Stem definition | Drug id | CAS RN |
---|---|---|
1722 | 1665-48-1 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.30 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 206.61 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 13, 1962 | FDA | KING PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Accidental death | 238.57 | 13.85 | 59 | 11086 | 1685 | 50592294 |
Completed suicide | 210.44 | 13.85 | 197 | 10948 | 131692 | 50462287 |
Drug hypersensitivity | 184.26 | 13.85 | 250 | 10895 | 250760 | 50343219 |
Toxicity to various agents | 160.91 | 13.85 | 215 | 10930 | 212284 | 50381695 |
Serotonin syndrome | 59.85 | 13.85 | 47 | 11098 | 24666 | 50569313 |
Deep vein thrombosis | 40.40 | 13.85 | 64 | 11081 | 73240 | 50520739 |
Anxiety | 40.00 | 13.85 | 107 | 11038 | 177499 | 50416480 |
Depression | 35.58 | 13.85 | 98 | 11047 | 165325 | 50428654 |
Overdose | 35.56 | 13.85 | 72 | 11073 | 99655 | 50494324 |
Purpura senile | 34.65 | 13.85 | 10 | 11135 | 519 | 50593460 |
Clonus | 33.52 | 13.85 | 17 | 11128 | 4158 | 50589821 |
Injury | 31.60 | 13.85 | 46 | 11099 | 48879 | 50545100 |
Fibromyalgia | 30.08 | 13.85 | 43 | 11102 | 44935 | 50549044 |
Tarsal tunnel syndrome | 30.08 | 13.85 | 9 | 11136 | 530 | 50593449 |
Resorption bone increased | 24.52 | 13.85 | 9 | 11136 | 1002 | 50592977 |
Foot fracture | 24.49 | 13.85 | 26 | 11119 | 20065 | 50573914 |
Muscle rigidity | 24.45 | 13.85 | 19 | 11126 | 9810 | 50584169 |
Intervertebral disc protrusion | 24.17 | 13.85 | 26 | 11119 | 20367 | 50573612 |
Ankle fracture | 24.03 | 13.85 | 23 | 11122 | 15699 | 50578280 |
Drug ineffective | 23.55 | 13.85 | 97 | 11048 | 819236 | 49774743 |
Autonomic nervous system imbalance | 22.99 | 13.85 | 11 | 11134 | 2374 | 50591605 |
Vestibular disorder | 22.53 | 13.85 | 9 | 11136 | 1260 | 50592719 |
Infusion related reaction | 22.34 | 13.85 | 5 | 11140 | 169552 | 50424427 |
Neck pain | 21.28 | 13.85 | 42 | 11103 | 57025 | 50536954 |
Off label use | 20.90 | 13.85 | 46 | 11099 | 474380 | 50119599 |
Migraine | 20.73 | 13.85 | 49 | 11096 | 75231 | 50518748 |
Suicidal behaviour | 20.20 | 13.85 | 10 | 11135 | 2324 | 50591655 |
Vertigo positional | 19.51 | 13.85 | 10 | 11135 | 2501 | 50591478 |
Neutropenia | 18.25 | 13.85 | 5 | 11140 | 147960 | 50446019 |
Muscle spasms | 17.42 | 13.85 | 64 | 11081 | 125489 | 50468490 |
Concussion | 17.37 | 13.85 | 14 | 11131 | 7614 | 50586365 |
Systemic lupus erythematosus | 16.88 | 13.85 | 5 | 11140 | 140617 | 50453362 |
Drug withdrawal syndrome | 16.80 | 13.85 | 24 | 11121 | 25057 | 50568922 |
Lower limb fracture | 16.59 | 13.85 | 18 | 11127 | 14228 | 50579751 |
Drug abuse | 16.52 | 13.85 | 39 | 11106 | 59807 | 50534172 |
Temporomandibular joint syndrome | 16.30 | 13.85 | 10 | 11135 | 3529 | 50590450 |
Joint swelling | 16.30 | 13.85 | 18 | 11127 | 245268 | 50348711 |
Respiratory arrest | 16.24 | 13.85 | 26 | 11119 | 29983 | 50563996 |
Spinal stenosis | 15.57 | 13.85 | 17 | 11128 | 13533 | 50580446 |
Mydriasis | 15.21 | 13.85 | 15 | 11130 | 10612 | 50583367 |
Treatment failure | 14.62 | 13.85 | 6 | 11139 | 137631 | 50456348 |
Thrombocytopenia | 14.51 | 13.85 | 5 | 11140 | 127668 | 50466311 |
Road traffic accident | 14.43 | 13.85 | 22 | 11123 | 24330 | 50569649 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 86.47 | 20.52 | 75 | 3217 | 90171 | 29481064 |
Toxicity to various agents | 86.36 | 20.52 | 101 | 3191 | 173560 | 29397675 |
Accidental death | 64.69 | 20.52 | 19 | 3273 | 2099 | 29569136 |
Drug hypersensitivity | 46.40 | 20.52 | 47 | 3245 | 68359 | 29502876 |
Coronary artery disease | 36.78 | 20.52 | 34 | 3258 | 44156 | 29527079 |
Overdose | 24.79 | 20.52 | 37 | 3255 | 79782 | 29491453 |
Back pain | 24.35 | 20.52 | 42 | 3250 | 102242 | 29468993 |
Drug withdrawal syndrome | 23.57 | 20.52 | 18 | 3274 | 17966 | 29553269 |
Body height decreased | 22.99 | 20.52 | 10 | 3282 | 3440 | 29567795 |
Depression | 22.99 | 20.52 | 37 | 3255 | 85110 | 29486125 |
Back injury | 22.90 | 20.52 | 10 | 3282 | 3474 | 29567761 |
Cerebral vasoconstriction | 21.71 | 20.52 | 5 | 3287 | 211 | 29571024 |
Emotional distress | 20.65 | 20.52 | 15 | 3277 | 13880 | 29557355 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 340.99 | 15.31 | 292 | 10776 | 224122 | 64263542 |
Accidental death | 292.84 | 15.31 | 77 | 10991 | 3648 | 64484016 |
Toxicity to various agents | 248.98 | 15.31 | 308 | 10760 | 363205 | 64124459 |
Drug hypersensitivity | 226.05 | 15.31 | 239 | 10829 | 237576 | 64250088 |
Serotonin syndrome | 73.69 | 15.31 | 58 | 11010 | 39224 | 64448440 |
Overdose | 69.27 | 15.31 | 109 | 10959 | 159457 | 64328207 |
Anxiety | 55.22 | 15.31 | 113 | 10955 | 202536 | 64285128 |
Depression | 43.89 | 15.31 | 97 | 10971 | 183194 | 64304470 |
Coronary artery disease | 42.29 | 15.31 | 52 | 11016 | 60381 | 64427283 |
Injury | 40.51 | 15.31 | 49 | 11019 | 55943 | 64431721 |
Clonus | 40.17 | 15.31 | 20 | 11048 | 6047 | 64481617 |
Deep vein thrombosis | 37.73 | 15.31 | 66 | 11002 | 105116 | 64382548 |
Tarsal tunnel syndrome | 32.88 | 15.31 | 9 | 11059 | 496 | 64487168 |
Purpura senile | 32.77 | 15.31 | 9 | 11059 | 502 | 64487162 |
Drug withdrawal syndrome | 28.75 | 15.31 | 31 | 11037 | 31260 | 64456404 |
Neutropenia | 27.86 | 15.31 | 4 | 11064 | 239620 | 64248044 |
Myocardial infarction | 27.22 | 15.31 | 76 | 10992 | 165745 | 64321919 |
Hyperlipidaemia | 27.01 | 15.31 | 26 | 11042 | 22950 | 64464714 |
Muscle rigidity | 26.88 | 15.31 | 23 | 11045 | 17450 | 64470214 |
Emotional distress | 26.81 | 15.31 | 32 | 11036 | 36006 | 64451658 |
Hyperreflexia | 26.33 | 15.31 | 16 | 11052 | 7132 | 64480532 |
Off label use | 25.95 | 15.31 | 43 | 11025 | 632763 | 63854901 |
Intervertebral disc protrusion | 25.93 | 15.31 | 24 | 11044 | 20167 | 64467497 |
Resorption bone increased | 25.45 | 15.31 | 9 | 11059 | 1159 | 64486505 |
Vertigo positional | 23.52 | 15.31 | 11 | 11057 | 2900 | 64484764 |
Vestibular disorder | 22.75 | 15.31 | 10 | 11058 | 2283 | 64485381 |
Back injury | 22.67 | 15.31 | 15 | 11053 | 7742 | 64479922 |
Respiratory arrest | 21.30 | 15.31 | 35 | 11033 | 52950 | 64434714 |
Mydriasis | 21.23 | 15.31 | 19 | 11049 | 15293 | 64472371 |
Gastrooesophageal reflux disease | 21.00 | 15.31 | 45 | 11023 | 83098 | 64404566 |
Fibromyalgia | 20.68 | 15.31 | 28 | 11040 | 35703 | 64451961 |
Poisoning | 20.67 | 15.31 | 22 | 11046 | 21857 | 64465807 |
Muscle spasms | 19.66 | 15.31 | 61 | 11007 | 140962 | 64346702 |
Thrombocytopenia | 19.53 | 15.31 | 7 | 11061 | 223794 | 64263870 |
Migraine | 19.50 | 15.31 | 37 | 11031 | 62640 | 64425024 |
Road traffic accident | 19.19 | 15.31 | 25 | 11043 | 30720 | 64456944 |
Spinal stenosis | 18.75 | 15.31 | 17 | 11051 | 13914 | 64473750 |
Infusion related reaction | 18.53 | 15.31 | 3 | 11065 | 164464 | 64323200 |
Body height decreased | 18.27 | 15.31 | 13 | 11055 | 7541 | 64480123 |
Cardio-respiratory arrest | 18.04 | 15.31 | 47 | 11021 | 98346 | 64389318 |
Febrile neutropenia | 17.92 | 15.31 | 5 | 11063 | 187652 | 64300012 |
Chest pain | 17.87 | 15.31 | 84 | 10984 | 235896 | 64251768 |
Drug dependence | 17.62 | 15.31 | 25 | 11043 | 33287 | 64454377 |
Suicidal behaviour | 17.60 | 15.31 | 9 | 11059 | 2878 | 64484786 |
Neck pain | 17.53 | 15.31 | 35 | 11033 | 61498 | 64426166 |
Bronchitis | 17.01 | 15.31 | 49 | 11019 | 108694 | 64378970 |
Drug abuser | 16.42 | 15.31 | 11 | 11057 | 5797 | 64481867 |
Diarrhoea | 15.91 | 15.31 | 67 | 11001 | 722637 | 63765027 |
Pain | 15.56 | 15.31 | 154 | 10914 | 553357 | 63934307 |
Back pain | 15.39 | 15.31 | 84 | 10984 | 250087 | 64237577 |
None
Source | Code | Description |
---|---|---|
MeSH PA | D009465 | Neuromuscular Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
FDA PE | N0000175730 | Centrally-mediated Muscle Relaxation |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Spasticity | indication | 221360009 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Hemolytic anemia | contraindication | 61261009 | DOID:583 |
Acute hepatic failure | contraindication | 197270009 | |
Chronic Hepatic Disease | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.45 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
800MG | SKELAXIN | KING PHARMS | N013217 | Aug. 30, 2002 | RX | TABLET | ORAL | 7122566 | Feb. 6, 2026 | TREATMENT OF MUSCULOSKELETAL CONDITIONS |
None
None
ID | Source |
---|---|
4018807 | VUID |
N0000147110 | NUI |
D00773 | KEGG_DRUG |
4018807 | VANDF |
C0163055 | UMLSCUI |
CHEBI:6797 | CHEBI |
CHEMBL1079604 | ChEMBL_ID |
DB00660 | DRUGBANK_ID |
15459 | PUBCHEM_CID |
1027 | INN_ID |
C011301 | MESH_SUPPLEMENTAL_RECORD_UI |
7609 | IUPHAR_LIGAND_ID |
1NMA9J598Y | UNII |
204315 | RXNORM |
1680 | MMSL |
172287 | MMSL |
5062 | MMSL |
d00964 | MMSL |
001673 | NDDF |
404863006 | SNOMEDCT_US |
87599003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1745 | TABLET | 400 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1745 | TABLET | 400 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1748 | TABLET | 800 mg | ORAL | NDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0448 | TABLET | 800 mg | ORAL | ANDA | 17 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0276-0508 | TABLET | 400 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1435 | TABLET | 800 mg | ORAL | ANDA | 19 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2341 | TABLET | 800 mg | ORAL | ANDA | 19 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6831 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6831 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-002 | TABLET | 800 mg | ORAL | NDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-144 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
SKELAXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-524 | TABLET | 800 mg | ORAL | NDA | 20 sections |
SKELAXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-207 | TABLET | 800 mg | ORAL | NDA | 20 sections |
METAXALONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-346 | TABLET | 800 mg | ORAL | NDA | 20 sections |
Skelaxin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-123 | TABLET | 800 mg | ORAL | NDA | 21 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-585 | TABLET | 800 mg | ORAL | ANDA | 19 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-724 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-040 | TABLET | 800 mg | ORAL | NDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-587 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
METAXALONE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42549-650 | TABLET | 800 mg | ORAL | NDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-942 | TABLET | 800 mg | ORAL | ANDA | 19 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-985 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3174 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3650 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3670 | TABLET | 800 mg | ORAL | ANDA | 19 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4448 | TABLET | 800 mg | ORAL | ANDA | 21 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-323 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-474 | TABLET | 400 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-530 | TABLET | 800 mg | ORAL | ANDA | 20 sections |
Metaxalone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50436-0449 | TABLET | 800 mg | ORAL | ANDA | 19 sections |